Literature DB >> 32442069

Locoregional Management After Neoadjuvant Chemotherapy.

Monica Morrow1, Atif J Khan2.   

Abstract

Mesh：

Year:  2020        PMID： 32442069      PMCID： PMC7343435          DOI： 10.1200/JCO.19.02576

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  61 in total

1.  Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.

Authors:  Kelly K Hunt; Min Yi; Elizabeth A Mittendorf; Cynthia Guerrero; Gildy V Babiera; Isabelle Bedrosian; Rosa F Hwang; Henry M Kuerer; Merrick I Ross; Funda Meric-Bernstam
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

Review 2.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.

Authors:  Michael L Marinovich; Nehmat Houssami; Petra Macaskill; Francesco Sardanelli; Les Irwig; Eleftherios P Mamounas; Gunter von Minckwitz; Meagan E Brennan; Stefano Ciatto
Journal:  J Natl Cancer Inst       Date:  2013-01-07       Impact factor: 13.506

3.  Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.

Authors:  Stephanie M Wong; Anna Weiss; Elizabeth A Mittendorf; Tari A King; Mehra Golshan
Journal:  Ann Surg Oncol       Date:  2019-07-24       Impact factor: 5.344

4.  Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.

Authors:  Bruce G Haffty; Linda M McCall; Karla V Ballman; Thomas A Buchholz; Kelly K Hunt; Judy C Boughey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-05-11       Impact factor: 7.038

5.  Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Authors:  Eugene H Huang; Susan L Tucker; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Aman U Buzdar; Vicente Valero; George H Perkins; Naomi R Schechter; Kelly K Hunt; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

6.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Authors:  Norikazu Masuda; Soo-Jung Lee; Shoichiro Ohtani; Young-Hyuck Im; Eun-Sook Lee; Isao Yokota; Katsumasa Kuroi; Seock-Ah Im; Byeong-Woo Park; Sung-Bae Kim; Yasuhiro Yanagita; Shinji Ohno; Shintaro Takao; Kenjiro Aogi; Hiroji Iwata; Joon Jeong; Aeree Kim; Kyong-Hwa Park; Hironobu Sasano; Yasuo Ohashi; Masakazu Toi
Journal:  N Engl J Med       Date:  2017-06-01       Impact factor: 91.245

7.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Ann Brown; Roy Smith; Eleftherios P Mamounas; Bernard Fisher; Richard Margolese; Heather Theoret; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

8.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

Authors:  Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.

Authors:  Amit K Garg; Eric A Strom; Marsha D McNeese; Aman U Buzdar; Gabriel N Hortobagyi; Henry M Kuerer; George H Perkins; S Eva Singletary; Kelly K Hunt; Asyegul Sahin; Naomi Schechter; Vicente Valero; Susan L Tucker; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

10.  Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer
Journal:  N Engl J Med       Date:  2018-12-05       Impact factor: 176.079
View more
  6 in total

1.  Reply to the letter on sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer.

Authors:  Andrea P Damin
Journal:  Breast Cancer Res Treat       Date:  2021-06-08       Impact factor: 4.872

2.  Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.

Authors:  Benjamin D Smith; Matthew P Goetz; Judy C Boughey
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

3.  Comparison of two different surgical strategies for breast cancer patients treated with mastectomy plus sentinel lymph node biopsy.

Authors:  Xing Zhang; Qian Shen; Yu-Jie Hu
Journal:  Updates Surg       Date:  2021-06-10

4.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Authors:  Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544

5.  Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.

Authors:  Ariane A van Loevezijn; Marieke E M van der Noordaa; Marcel P M Stokkel; Erik D van Werkhoven; Emma J Groen; Claudette E Loo; Paula H M Elkhuizen; Gabe S Sonke; Nicola S Russell; Frederieke H van Duijnhoven; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2022-03-03       Impact factor: 4.872

6.  Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.

Authors:  Steffi Hartmann; Thorsten Kühn; Michael Hauptmann; Elmar Stickeler; Marc Thill; Michael P Lux; Sarah Fröhlich; Franziska Ruf; Sibylle Loibl; Jens-Uwe Blohmer; Hans-Christian Kolberg; Elisabeth Thiemann; Michael Weigel; Christine Solbach; Gabriele Kaltenecker; Peter Paluchowski; Michael G Schrauder; Stefan Paepke; Dirk Watermann; Markus Hahn; Maria Hufnagel; Jutta Lefarth; Michael Untch; Maggie Banys-Paluchowski
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-13       Impact factor: 2.754
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.